Articles
We have yet another company moving towards a pivotal trial for hair regrowth in 2020. On June 4, 2020, Follica issued a press release to announce a positive ‘end of phase 2 meeting’ with the US FDA in preparation to begin a phase 3 trial this year. The release also outlines details of Follica’s phase…
Read More
US Male Phase 2 Pyrilutamide Trial Underway: Update (3/1/22) Consistent progress is the M.O. of Kintor Pharma. On March 1, 2022 it was announced that the first patients in a US phase 2 trial for males have received dosing. The four cohorts in the trial will receive topical dosing of either 2.5 mg pyrilutamide twice…
Read More
Update (6/22/20) The Manager of Recruitment at the California Dermatology & Clinical Research Institute reached out to me over the weekend to let me know that their site is still seeking participants for the HST-001 trial. Recruitment for the trial is scheduled to close in about 3 weeks so if you live in the San…
Read More
Today, HairClone sent out its latest newsletter and first official update of 2020. Newsletter May 2020 Here are the important bullet points from HairClone’s latest newsletter including an invitation to complete a survey for the company: Business News In Oct 2019, we were successful in winning a significant 15 month grant from the UK Government…
Read More
Histogen Doses First Patient In 1B/2A Trial – Update 6/2/20 Histogen has wasted no time in getting their latest trial of HST-001 (HSC) underway. On June 1, 2020, the company sent out a press release to announce the first male patient has been dosed in their latest trial of HSC. Positive developments seem to be…
Read More
Follicle Thought is pleased to present an exclusive look at a newcomer in the hair loss treatment industry, Triple Hair of Canada. Triple Hair’s Story Triple Hair was founded by Dr. Houfar Sekhavat, an opthalmologist based in Moncton, Canada. It was Dr. Sekhavat’s own experience with androgenic alopecia which lead him to seek out a…
Read More
Today, I’m happy to be sharing a “never seen online before” poster of a L’Oreal research project involving the creation of hair follicle organoids in a dish. This type of work is commonly referred to as “hair cloning” – the ability to create brand new hair follicles outside the body using various types of follicle…
Read More
Phase 2 Trial Of Topical FOL-005 Has Resumed- Update 6/9/20 After a nearly 3 month intermission due to coronavirus restraints, Follicum is now able to continue recruitment for its phase 2 trial of a topical FOL-005 formulation. In addition to restarting the trial, Follicum has enlisted a third study center, CentroDerm of Wuppertal, Germany, to…
Read More
Replicel Terminates License With Shiseido: Update (12/21/21) Two months after Replicel announced that it was entering arbitration proceedings with Shiseido, the company has announced today that it has terminated its license agreement with Shiseido. The license agreement between Replicel and Shiseido dates back to 2013 when Shiseido paid an upfront fee to gain the rights…
Read More
Histogen is finally becoming a publicly traded company in 2020 after latest merger deal. On January 28, 2020, Histogen and Conatus Pharmaceuticals issued a press release announcing a definitive merger agreement between the two companies. Like Histogen, Conatus Pharmaceuticals is a biotech company based in San Diego, CA. Conatus has been publicly traded on Nasdaq…
Read More